Study summary
A similar approach with pembrolizumab did not significantly improve survival
What was tested
Pembrolizumab added to chemotherapy before and after surgery, against chemotherapy with placebo, for locally advanced stomach and gastroesophageal junction cancer.
What they found
- Median survival was 71.8 vs 55.7 months, but the difference was not statistically significant (hazard ratio 0.86).
- Side effects were similar between groups.
What it means
Shows results can differ between similar drugs and chemotherapy backbones; MATTERHORN used FLOT for everyone.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.